RecruitingNCT06889818

Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)

Sponsor

Ewha Womans University Mokdong Hospital

Enrollment

4,000 participants

Start Date

Feb 24, 2025

Study Type

OBSERVATIONAL

Conditions

Dementia Alzheimer Disease Mild Cognitive Impairment Subjective Cognitive Decline (SCD)

Summary

The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This is a real-world registry study in South Korea tracking patients who are being evaluated for or treated with newly approved Alzheimer's disease medications (like lecanemab or donanemab). It collects data on how well these drugs work and what side effects occur in everyday clinical settings. **You may be eligible if...** - You are 19 or older - You are being evaluated for or have decided to start a newly approved Alzheimer's treatment (approved after 2021) - You have had an amyloid PET scan to confirm amyloid buildup in the brain **You may NOT be eligible if...** - You are under 19 - You have not undergone amyloid PET confirmation - You are unwilling to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.